

LISTA DE LUCRĂRI CONF.DR.SABINA ANTONIU

I. **Teza doctorat** sustinuta in anul 2008, conducator de doctorat Prof Traian Mihaescu

Titlu: FACTORI PROGNOSTICI TERAPEUTICI IN BPOC-UL SEVER

II. CARTI SI CAPITOLE DE CARTE

CARTI

SA. Antoniu, M Lusuardi, M Carone, C Donner. *L'Aggiornamento Continuo in Pneumologia: Situazione Internazionale e Proposta di un Modello Operativo in Italia (Continuing Medical Education in Pulmonary Disease: International Situation and Proposal of an Operational Model in Italy).* Edi Aipo Scientifica, Italia ISBN 88-87398-32-1 (2002).

*Nursing paliativ si medicina paliativa: note de curs. Sub redactia **Sabina Antoniu.** Editura G T Popa UMF Iasi 2013, ISBN 978-606-544-191-0*

CAPITOLE DE CARTE

Antoniu SA, Arghir O. *Traietoria exacerbarilor BPOC intre reabilitarea precoce si paliatia terminala. In Recomandari de diagnostic si tratament in bronhopneumopatia obstructiva cronica. Sub redactia : Ruxandra Ulmeanu, Cristian Oancea, Ariadna Fildan, Florin Mihaltan. Editura Medicala, Bucuresti, 2019, ISBN 978-973-39-0870-8*

*Carone M, **Antoniu SA.** Humanistic outcomes and quality of life. In Long-Term Oxygen Therapy: New Insights & Perspectives. Edited by Dal Negro R. W. & Hodder R. Springer 2012, ISSN 978-88-470-2580-6b,*

*Antohe I, **Antoniu S.** Ingrijirile paliative la pacientii cu afectiuni cardiovasculare. In Bolile Cardiovasculare la varstnici. Sub redactia: Viviana Aursulesei, Florin Mitu, Ioana Alexa, Editura Polirom 2015 (pagini 881-825)*

SA Antoniu, T Mihaescu. *Pneumonia. În Patologia Pulmonară a Vârstnicului. Sub redacția Prof V Tudorache, Prof F Mihălțan, Prof T Mihaescu. Editura Didactică și Pedagogică RA. 2004 (pagini 68-81). ISBN: 973-30-1324-2*

SA Antoniu, T Mihaescu. *Tuberculoza. În Patologia Pulmonară a Vârstnicului. Sub redacția Prof V Tudorache, Prof F Mihălțan, Prof T Mihaescu. Editura Didactică și Pedagogică RA. 2004 (pagini 82-89). ISBN: 973-30-1324-2*

III. LISTA ARTICOLE IN EXTENSO PUBLicate IN REVISTE INDEXATE IN BAZE DE DATE INTERNATIONALE CA AUTOR SI CA SI CO-AUTOR

ISI AUTOR

1. **Antoniu SA,** Buculei I, , Mihaltan F, Crisan Dabija R, Trofor A. Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review. Expert Opin Pharmacother 2020 Early access, **IF pentru 2019=2.87.**
2. Alexa T, **Antoniu SA(autor corespondent),** Alexa I, Ilie A, Marinca M, Gafton B, Stefaniu R. Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. Expert Review of Anticancer Therapy 2020 Early access, **IF pentru 2019=3.57**

3. **Antoniou SA**, Rajnoveanu R, Grigore M, Antohe I. Pharmacotherapy options in pulmonary alveolar proteinosis. *Expert Opin Pharmacother* 2020 21(11): 1359-66. **IF pentru 2019=2,87**
4. **Antoniou SA**, Rajnoveanu R, Ulmeanu R, Mihaltan F, Grigore M. Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease. *Expert Opin Pharmacother* 2020 21(9): 997-1004. **IF pentru 2019=2,87**
5. **Antoniou SA**, Apostol A, Boiculese, LV. Extra-respiratory symptoms in patients hospitalized for a COPD exacerbation: Prevalence, clinical burden and their impact on functional status. *Clinical Respiratory Journal* 2019 13(12):735-40, **IF=1.514**
6. **Antoniou SA**. Investigational inhaled therapies for non-CF bronchiectasis. *Expert Opin Investig Drugs*. 2018 Feb;27(2):139-146, **IF =4.03** ISSN: 1354-3784.
7. **Antoniou SA**. Benralizumab as a potential treatment of asthma. *Expert Biol Ther*. 2017 Jul;17(7):895-900, **IF =3.97**, ISSN: 1478-7210.
8. **Antoniou SA**. Lebrikizumab for the treatment of asthma. *Expert Opin Investig Drugs*. 2016 Oct;25(10):1239-49, **IF=4.03**, ISSN= 1354-3784,
9. **Antoniou SA**, Boiculese LV. Palliative care outcome measures in COPD patients: a conceptual review. *Expert Rev Pharmacoecon Outcomes Res*. 2016;16(2):267-74. **IF=1.78**, ISSN: ISSN: 1473-7167,
10. **Antoniou SA**, Petrescu E, Stanescu R, Anisie E, Boiculese L. Impact of fatigue in patients with chronic obstructive pulmonary disease: results from an exploratory study. *Ther Adv Respir Dis*. 2016 Feb;10(1):26-33. **IF=2.74**, ISSN: 1753-4658,
11. Ulmeanu R, Antohe I, Anisie E, **Antoniou SA**. Nivolumab for advanced non-small lung cancer therapy: an evaluation of a phase III study. *Expert Review of Anticancer Therapy* 2016;16(2):165-167, **IF 2.21**, ISSN: 1473-7140
12. Ruxandra U, **Antoniou SA**, Mihaltan F, Boisteanu D. Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2015;16(10):1539-41. ISSN: **IF=3.54**, ISSN: 1465-6566
13. **Antoniou S**. Novel inhaled combined antibiotic formulations in the treatment of *Pseudomonas aeruginosa* airways infections in cystic fibrosis. *Expert Rev Anti Infect Ther*. 2015 Jul;13(7):897-905., **IF=3.54**, ISSN: 1478-7210
14. **Antoniou SA**, Ungureanu D. Measuring fatigue as a symptom in COPD: From descriptors and questionnaires to the importance of the problem. *Chron Respir Dis*. 2015 Aug;12(3):179-88. **IF=1.64**, ISSN: 1479-9723
15. **Antoniou SA**. Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease. *Expert Opin Ther Targets*. 2014 Nov;18(11):1285-92. **IF=5.13**, ISSN: 1478-7210
16. Drug VL, **Antoniou SA**. Efficacy of budesonide in collagenous colitis. *Expert Opin Pharmacother*. 2014 Oct;15(15):2277-9, **IF=3.53** ISSN: 1465-6566
17. Mihălțan FD, **Antoniou SA**, Ulmeanu R. Asthma and pregnancy: therapeutic challenges. *Arch Gynecol Obstet*. 2014 Oct;290(4):621-7. **IF=1.36**, ISSN; 0932-0067.
18. **Antoniou S**. Bedoradrine for treating asthma and chronic obstructive pulmonary disease. *Expert Opin Investig Drugs*. 2014 Aug;23(8):1149-56, **IF=5.52**, ISSN: 1354-3784
19. **Antoniou SA**, Dimofte G, Ungureanu D. Immune therapies for malignant mesothelioma. *Expert Rev Anticancer Ther*. 2014 Aug;14(8):965-73. **IF=2.24** ISSN: 1473-7140
20. **Antoniou S**. Epratuzumab for systemic lupus erythematosus. *Expert Opin Biol Ther*. 2014 Jul;14(7):1045-7. **IF=3.74**, ISSN: 1471-2598
21. **Antoniou SA**, Mihaltan F. Outcome measures for palliative oxygen therapy: relevance and practical utility. *Expert Rev Pharmacoecon Outcomes Res*. 2014 Jun;14(3):417-23, **IF=1.66**, ISSN: 1473-7167
22. **Antoniou SA**, Puiu A, Zaharia B, Azoicai D. Health status during hospitalisations for chronic obstructive pulmonary disease exacerbations: the validity of the Clinical COPD Questionnaire. *Expert Rev Pharmacoecon Outcomes Res*. 2014 Apr;14(2):283-7. **IF=1.66**, ISSN: 1473-7167
23. Râjnoveanu RM, **Antoniou S**, Ulmeanu R. Combined long-acting bronchodilator single therapy for COPD. *Expert Opin Pharmacother*. 2014 Jan;15(1):139-42. **IF=3.53** ISSN: 1465-6566,

24. **Antoniou S.** Outpatient palliative care effectiveness: both patients and caregivers can gain. *Expert Rev Pharmacoecon Outcomes Res.* 2013 Oct;13(5):575-7. **IF=1.87**, ISSN: 1473-7167
25. **Antoniou SA.** Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012). *Expert Opin Investig Drugs.* 2013 Nov;22(11):1453-64, **IF= 5.43**, ISSN: 1354-3784,
26. **Antoniou SA**, Carone M. Hospitalizations for chronic obstructive pulmonary disease exacerbations and their impact on disease and subsequent morbidity and mortality. *Expert Rev Pharmacoecon Outcomes Res.* 2013 Apr;13(2):187-9. **IF=1.87**, ISSN: 1473-7167
27. **Antoniou S**, Azoicai D. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. *Expert Opin Investig Drugs.* 2013 May;22(5):671-3, **IF=5.43**, ISSN: 1354-3784
28. **Antoniou SA**, Antohe I. Evaluation of inhaled tiotropium in asthma, uncontrolled with standard combination therapy. *Expert Opin Pharmacother.* 2013 May;14(7):967-9. **IF=3.08** ISSN: 1465-6566,
29. **Antoniou SA.** Monoclonal antibodies for asthma and chronic obstructive pulmonary disease. *Expert Opin Biol Ther.* 2013 Feb;13(2):257-68. **IF=3.65**, ISSN: 1471-2598
30. Antohe I, Croitoru R, **Antoniou S.** Tralokinumab for uncontrolled asthma. *Expert Opin Biol Ther.* 2013 Feb;13(2):323-6. **IF=3.65** ISSN: 1471-2598
31. Azoicai D, **Antoniou SA.** MP-376 (Aeroquin) for chronic *Pseudomonas aeruginosa* infections. *Expert Opin Investig Drugs.* 2013 Feb;22(2):267-76, **IF=5.43**, ISSN: 1354-3784
32. **Antoniou SA.** Targeting PDGF pathway in pulmonary arterial hypertension. *Expert Opin Ther Targets.* 2012 Nov;16(11):1055-63. **IF: 4.13**, ISSN: 1478-7210
33. **Antoniou SA.** Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. *Expert Opin Investig Drugs.* 2012 Nov;21(11):1607-18, **IF=4.74**, ISSN: 1354-3784
34. **Antoniou SA.** Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. *Expert Opin Ther Targets* 2012 16(4): 355-363, **IF: 4.13**, ISSN: 1478-7210,
35. **Antoniou SA**, Cojocaru I. Inhaled colistin for lower respiratory tract infections. *Expert Opin Drug Deliv* 2012 9(3): 333-342, **IF: 4.86**, 1742-5247
36. **Antoniou SA**, Trofor, AC. Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease. *Expert Opin Pharmacother* 2011 12(16): 2595-2597 **Impact factor 3.20**, ISSN: 1465-6566
37. **Antoniou SA.** Discontinued drugs 2010: rheumatology, allergy and dermatology, pulmonary. *Expert Opin Investig Drugs* 2011 20(9): 1175-1187, ISSN: 1354-3784, **Impact factor 5.27**
38. **Antoniou SA.** Terguride for pulmonary arterial hypertension. *Expert Opin Ther Targets* 2011 15(11): 1333-1335 **Impact factor 3.71**, ISSN: 1478-7210
39. **Antoniou SA**, Trofor AC. Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. *Expert Opin Pharmacother* 2011 12(7): 1191-1194 **Impact factor 3.20**, ISSN: 1465-6566
40. **Antoniou SA.** Inhaled phosphodiesterase type 5 inhibitors for cystic fibrosis: a new therapy for a systemic disease ? *Expert Opin Investig Drugs* 2011 20(5): 713-715, ISSN: 1354-3784 **Impact factor 5.27**
41. **Antoniou SA.** Acridinium bromide in experimental asthma. *Expert Opin Investig Drugs* 2011 20(6): 871-873, ISSN: 1354-3784, **Impact factor 5.27**
42. **Antoniou SA.** Targeting the Toll-like receptor 7 pathway in asthma: a potential immunomodulatory approach ? *Expert Opin Ther Targets* 2011 15(5): 667-669 **Impact factor 3.71**, ISSN: 1478-7210
43. **Antoniou SA.** Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. *Expert Opin Investig Drugs* 2011 20(3): 423-425, ISSN: 1354-3784 **Impact factor 5.27**
44. **Antoniou SA.** Therapeutic approaches in hereditary angioedema. *Clin Rev Allergy Immunol* 2011 41(1):114-122 **Impact factor 3.43**, ISSN : 1080-0549
45. **Antoniou SA**, Sampablo I, Carone M. Tiotropium in the treatment of asthma. *Expert Opin Pharmacother.* 2011 12(3): 489-491 **Impact factor 3.20, prim autor**, ISSN: 1465-6566

46. **Antoniou SA.** Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Expert Opin Ther Targets 2011 15(3): 351-353 **Impact factor 3.71, ISSN: 1478-7210**
47. **Antoniou SA.** Pitracinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Investig Drugs 2010 11(11): 1286-1294 **Impact factor 3.39, ISSN: 1472-4472**
48. **Antoniou SA.** Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T cell lymphomas and asthma. Curr Opin Mol Ther 2010 12(6): 770-779 **Impact factor 4.02, ISSN: 1464-8431**
49. **Antoniou SA, Cojocaru I.** Pitracinra for asthma. Expert Opin Biol Ther 2010 10(11):1609-1615 **Impact factor 3.27, ISSN: 1471-2598**
50. **Antoniou SA.** Novel therapies for hypereosinophilic syndromes. Neth J Med 2010 68(1):304-10 **Impact factor 1.84, ISSN: 0300-2977**
51. **Antoniou SA.** GM-CSF pathway correction in pulmonary alveolar proteinosis. Expert Opin Biol Ther. 2010 10(9):1357- 1365 **Impact factor 3.27, ISSN: 1471-2598**
52. **Antoniou SA.** Raxibacumab for inhalational anthrax: an effective specific therapeutic approach. Expert Opin Investig Drugs 2010 19(7): 909-911, ISSN: 1354-3784, **Impact factor 4.33**
53. **Antoniou SA, Kolb MRJ.** Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs. 2010 13(5): 332-345 **Impact factor 2.78, ISSN: 1369-7056**
54. **Antoniou SA.** Enhancing the nitric oxide synthesis pathway in asthma: a plausible therapeutic approach? Curr Opin Investig Drugs. 2010 11(5): 543- 549 **Impact factor 3.39, ISSN: 1472-4472**
55. **Antoniou SA.** MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. Curr Opin Mol Ther. 2010 12(2): 233-239 **Impact factor 4.02, ISSN: 1464-8431**
56. **Antoniou SA.** Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets 2010 14(1):21-9 **Impact factor 3.64, ISSN: 1478-7210**
57. **Antoniou SA.** Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. Biomarkers 2010 15(2): 97-103 **Impact factor 2.09 ISSN: 1354-750X**
58. **Antoniou SA.** Challenges in targeting TNF alpha in asthma and COPD. Current Opinion in Investigational Drugs 2009 10 (5): 404-406. **Impact factor 3.54 ISSN: 1472-4472**
59. **Antoniou SA, Antoniu SA.** Fudosteine effects on mucin production Evaluation of: Rhee CK, Kang CM, You MB, et al. Expert Opin Investig Drugs 2009 18(1): 105-107, ISSN: 1354-3784 **Impact factor 4.21**
60. **Antoniou SA.** Discontinued drugs 2008: pulmonary and allergy. Expert Opin Investig Drugs 2009 18(12):1799-1805, **Impact factor 4.21, ISSN: 1354-3784,**
61. **Antoniou SA.** Cytokine antagonists for the treatment of asthma: progress to date. BioDrugs 2009; 23(4): 241-251 **Impact factor 3.5, ISSN: 1173-8804**
62. **Antoniou SA.** Golimumab for severe asthma. Expert Opin Investig Drugs 2009 18(9):1421-1423, **Impact factor 4.21 ISSN: 1354-3784**
63. **Antoniou SA.** Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia. Expert Opin Investig Drugs 2009 18(6):869-871, **Impact factor 4.21, ISSN: 1354-3784.**
64. **Antoniou SA.** Itraconazole for severe asthma with fungal sensitivity. Expert Opin Pharmacother. 2009 10(7):1231-1233 **Impact factor 2.01, ISSN: 1465-6566**
65. **Antoniou SA.** UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Expert Opin Pharmacother 2009 10(4):719-22 **Impact factor 2.01, ISSN: 1465-6566**
66. **Antoniou SA.** Daclizumab a novel corticosteroid-sparing therapy for asthma ? Expert Opin Investig Drugs. 2009 18(3): 369-371, **Impact factor 4.21, ISSN: 1354-3784**
67. **Antoniou SA.** Targeting platelet-derived growth factor with imatinib in idiopathic pulmonary arterial hypertension. Expert Opin Ther Targets. 2009 13(3): 381- 383 **Impact factor 3.71, ISSN: 1478-7210**
68. **Antoniou SA, Kolb MRJ.** Update on models of pulmonary fibrosis therapy for preclinical drug research. Expert Opinion on Drug Discovery 2009 4(9): 939-946 **Impact factor 1.35, ISSN 1746-0441**
69. **Antoniou SA.** Targeting the angiotensin pathway in idiopathic pulmonary fibrosis. Expert Opin Ther Targets 2008 12(12):1587- 1590 **Impact factor 4.03, ISSN: 1478-7210**

70. **Antoniou SA.** Discontinued drugs 2007: pulmonary, allergy, dermatological, gastrointestinal and arthritis drugs. *Expert Opin Investig Drugs.* 2008 17(11):1651-1661, **Impact factor 4.05**, ISSN: 1354-3784
71. **Antoniou SA.** Targeting endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. *Expert Opin Ther Targets.* 2008 12(9):1077-1084 **Impact factor 4.03**, ISSN: 1478-7210
72. **Antoniou SA, Mihaescu F, Ulmeanu R.** Anti-TNF-alpha therapies in chronic obstructive pulmonary diseases. *Expert Opin Investig Drugs.* 2008 17(8):1203- 1211, **Impact factor 4.05**, ISSN: 1354-3784
73. **Antoniou SA.** Somatostatin analogs for idiopathic pulmonary fibrosis therapy. *Expert Opin Investig Drugs.* 2008 17(7):1137-1140, **Impact factor 4.05**, ISSN: 1354-3784
74. **Antoniou SA.** PDE5 inhibitors for cystic fibrosis: can they also enhance chloride transport? *Expert Opin Investig Drugs.* 2008 17(6): 965-968, **Impact factor 4.05**, ISSN: 1354-3784
75. **Antoniou SA.** Bosentan for the treatment of idiopathic pulmonary fibrosis. *Expert Opin Investig Drugs* 2008 17(4): 611-614, **Impact factor 4.05**, ISSN: 1354-3784
76. **Antoniou SA, Mihaescu, T, Donner CF.** Pharmacotherapy of cough-variant asthma. *Expert Opin Pharmacother* 2007 8(17): 3012-3018 **Impact factor 1.70**, ISSN: 1465-6566
77. **Antoniou SA.** Infliximab for the therapy of chronic sarcoidosis. *Expert Opin Investig Drugs.* 2007 16(5):753-756, , **Impact factor 3.66**, ISSN: 1354-3784
78. **Antoniou SA, Mihaescu T, Donner CF.** Inhaled therapy for stable chronic obstructive pulmonary disease. *Expert Opin Pharmacother* 2007 8(6): 777-785 **Impact factor 1.70**, ISSN: 1465-6566
79. **Antoniou SA.** Cyclophosphamide for scleroderma interstitial lung disease. *Expert Opin Investig Drugs* 2007 16(3): 393- 395, , **Impact factor 3.66**, ISSN: 1354-3784
80. **Antoniou SA.** Formoterol as a rescue medication for asthma. *Expert Opin Pharmacother* 2006 7(17): 2439-2441 **Impact factor 1.73**, ISSN: 1465-6566
81. **Antoniou SA.** Etanercept for refractory asthma therapy. *Expert Opin Investig Drugs* 2006 15(10): 1279-128, ISSN: 1354-3784 **Impact factor 3.17**, ISSN: 1354-3784
82. **Antoniou SA.** Sildenafil for pulmonary arterial hypertension: when blue turns into white. *Expert Opin Pharmacother* 2006 7(13): 1801-1810 **Impact factor 1.73** ISSN: 1465-6566
83. **Antoniou SA.** Daily versus intermittent corticosteroids for the treatment of mild persistent asthma. *Expert Opin Pharmacother* 2006 7(9):1235-8 **Impact factor 1.73**, ISSN: 1465-6566
84. **Antoniou SA.** Histone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary disease. *Expert Opin Ther Targets* 2006 10(2): 329-332 **Impact factor 2.66**, ISSN: 1478-7210
85. **Antoniou SA.** Sildenafil citrate for the treatment of pulmonary arterial hypertension. *Expert Opin Pharmacother* 2006 7(6):825-8 **Impact factor 1.73**, ISSN: 1465-6566
86. **Antoniou SA.** Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. *Expert Opin Investig Drugs* 2005 14(11) : 1443-1447, **Impact factor 3.26**, ISSN: ISSN: 1354-3784
87. **Antoniou SA.** Systemic inflammation and inhaled corticosteroids in COPD. *Am J Respir Crit Care Med* 2009 179(2):170-170, **IF=10.68**, ISSN: 1073-449X
88. **Antoniou SA.** BENRALIZUMAB Anti-IL-5R alpha monoclonal antibody Treatment of asthma. *Drugs of the Future* 2014 39(7):463-467, IF=0.17, ISSN 0377-8282
89. **Antoniou SA.** Mepolizumab for Churg-Strauss syndrome. *Drugs of the Future* 2014 39(4):269-274, ISSN 0377-8282, IF=0.17
90. **Antoniou, SA.** AMATUXIMAB Chimeric Anti-Mesothelin Monoclonal Antibody Treatment of Mesothelioma. *Drugs of the Future* 2013 39(4):269-274, IF=0.25, ISSN 0377-8282
91. **Antoniou, SA.** A review on the use of sirolimus in lymphangioleiomyomatosis. *Drugs of the Future* 2013 38(3):181-186, IF=0.25, ISSN 0377-8282
92. **Antoniou SA.** Lambert-Eaton Myasthenic Syndrome: understanding and management advances. *Drugs of the Future* 2013 38(7):513-519, IF=0.25, ISSN 0377-8282
93. **Antoniou SA.** Effects of montelukast-desloratadine combination on early and late asthma responses. *Expert Opin Pharmacother.* 2009 10(15): 2577-2579 ISSN: 1465-6566 **Impact factor 2.01**
94. **Antoniou SA.** Phenotype/endotype-driven therapy in COPD: potential economic implications. *Expert Rev Pharmacoecon Outcomes Res.* 2013 Aug;13(4):421-3. **IF=1.87**, ISSN: 1473-7167

95. **Antoniou SA**, Pop CM. Ciclesonide therapy in asthma: a potential effect on small airway inflammation. *Expert Opin Pharmacother*. 2009 10(5): 917- 919 **Impact factor 2.01**, ISSN: 1465-6566
96. **Antoniou SA**. Nitric oxide donors and asthma. *Drugs of the Future* 2012 37(8): 571-6, ISSN: 0377-8282, IF=0.39
97. **Antoniou SA**. Matrix metalloproteinase inhibitors for chronic obstructive pulmonary disease. *Drugs of the Future* 2012 37(7): 523-9, , IF=0.39, ISSN: 0377-8282
98. Antoniu SA. Fresh from the designation pipeline: orphan drugs designated in the European Union (November - December 2014). *Expert Opinion on Orphan Drugs* 3(6):719-725, IF=0.46, ISSN 2167-8707
99. Antoniu SA. Fresh from the designation pipeline: orphan drugs recently designated in the European Union (August-October 2014). *Expert Opinion on Orphan Drugs* 3(3):321-328, IF=0.46, ISSN 2167-8707
100. Antoniu SA. Fresh from the designation pipeline: orphan drugs recently designated in the EU (June-July 2014): *Expert Opinion on Orphan Drugs* 2014 2(12):1309-313, IF=0.52, ISSN 2167-8707,
101. Antoniu SA. Fresh from the designation pipeline: orphan drugs recently designated in the EU (March-April 2014): *Expert Opinion on Orphan Drugs* 2014 2(19):1309-313, IF=0.52, ISSN 2167-8707,
102. Antoniu SA. Fresh from the designation pipeline: orphan drugs recently designated in the EU (December 2013-February 2014): *Expert Opinion on Orphan Drugs* 2014 2(6):635-641, IF=0.52, ISSN 2167-8707
103. Antoniu, SA. Fresh from the designation pipeline: orphan drugs recently designated in the European Union (September - November 2013). *Expert Opinion on Orphan Drugs* 2014 2(3):311-315, IF=0.52, ISSN 2167-8707

ISI –coautor

1. Rajnoveanu R, Rajnoveanu A, **Antoniou S**, Todea DA, Man MA, Davidescu L, Valeanu M, Groza AT, Sfirlea VG, Ulmeanu R. Work-related stress factors and coping behavior among pneumologists. *Acta Medica Mediterranea* 2020 36(5): 2893-2899, **IF=0.24 pt 2019**, ISSN online 2283-9720
2. Rajnoveanu R, Rajnoveanu A, Ardelean AB, Todea DA, Pop CM, **Antoniou S**, Motoc NS, Chis AF, , Fildan AP, Man MA Pulmonologists Adherence to the Chronic Obstructive Pulmonary Disease GOLD Guidelines: A Goal to Improve MEDICINA-LITHUANIA 2020 56 (9) Article Number: 422 , **IF= 1,2 pt 2019**, ISSN online 1648-9144
3. Alexa I, Alexa-Stratulat T, **Antoniou S**, Antohe I, Arghir O, Grigorescu C. Roflumilast in patients with advanced chronic obstructive pulmonary disease: towards a better-targeted use. *Expert Opin on Pharmacother* 2019 20 (1): 91-93, **IF=2.87**, ISSN: 1465-6566
4. Antohe I, **Antoniou S**, Gavrilovici C. Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction. *Expert Opin Pharmacother* 2018 19 (3): 287-9, **IF=3.03**, ISSN: 1465-6566
5. Zaharie, AM; **Antoniou, S**; Wynimko, Chorostowska J, Mihltan F, Deleanu o, Mahler B, Davidescu L, Arghir OC, Ulmeanu R. Romanian Pilot Study of Alpha-1 Antitrypsin Detection-Feasibility and Challenges *REVISTA DE CHIMIE* 2018 69 (5): 1152-5, **IF=1.6**, ISSN online 2668-8212
6. Carone M, **Antoniou S**, Baiardi P, Digilio VS, Jones PW, Bertolotti G; QuESS Group. Predictors of Mortality in Patients with COPD and Chronic Respiratory Failure: The Quality-of-Life Evaluation and Survival Study (QuESS): A Three-Year Study. *COPD*. 2016;13(2):130-8. **IF=2.57**, ISSN: 1541-2555
7. Otelea MR, Arghir O, Zugravu C, Naghi E, **Antoniou S**, Rascu A. *Revista de Chimie* 2018 Volume: 69 Issue: 2 Pages: 346-349, **IF =1.6**, ISSN 2537-5733
8. Azoicai T, **Antoniou SA**, Caruntu ID, Azoicai D, Antohe I, Gavrilovici C. Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus. *Expert review of clinical immunology* 2018 Volume: 14 Issue: 3 Pages: 175-177, **IF =3.90**, ISSN: 1744-666X

9. Gavrilovici C, Luca A, **Antoniou SA**, Gallaby K, Stefanescu R, Starcea M, Miron I, Bild V. How nephrotoxic is the cancer therapy in children ? *Farmacia* 2018, 66(2): 197-208, **IF =1.52**, ISSN: 0014-8237

Indexate ISI dar necotate(fara impact factor) – autor principal

10. **Antoniou SA**. Roflumilast as an add-on therapy to conventional inhalers in COPD-a cost-effectiveness analysis. *Journal of Comparative Effectiveness* 2011, 1(4):315-7
11. **Antoniou SA**. Health status and chronic obstructive pulmonary disease severity. *Expert Review of Pharmacoeconomics Outcomes Res* 2011 11(4): 399-401
12. **Antoniou SA**. Predictors of depression in chronic obstructive pulmonary disease patients. *Expert Rev of Respiratory Medicine* 2011 5(3):333-335
13. **Antoniou SA**. Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease. *Expert Review of Pharmacoeconomics Outcomes Res* 2010 10(2): 155-162
14. **Antoniou SA**. Descriptors of dyspnea in obstructive lung diseases. *Multidisciplinary Respiratory Medicine* 2010 5(3): 216-219
15. **Antoniou SA**. Adherence to inhaled therapy in COPD: effects on exacerbations and survival. *Expert Review on Pharmacoeconomics and Outcomes Research* 2010 10(2): 115-117.

Indexate BDI –autor principal

1. **Antoniou SA, Petrescu E, Stanescu R, Boiculese L**. Fatigue, disease burden and autoimmune systemic inflammation in normoxemic COPD patients. **Med Con** 2017 12(1):13-18. Indexata Index Copernicus
2. **Antoniou SA**. Adherence with inhaled therapy in asthma. *Med Con* 2011 Vol 6, No 2, 37–58 (**Indexata in Index Copernicus**)
3. **Antoniou SA**. Roflumilast for the treatment of respiratory disease: review of the phase II and III trials. *Clinical Investigation* 2011 1(10): 1413-1419 (**Indexata in Scholar Citation Index**)
4. **Antoniou SA**. Long-term effects of inhaled bronchodilators in stable chronic obstructive pulmonary disease. *Therapy*.2011 8(4): 431-441 (**Indexata Excerpta Medica, Scopus etc**)
5. **Antoniou SA**. Daclizumab: a potential asthma therapy? *Recent Pat Inflamm Allergy Drug Discov*. 2010 4(3): 214-219 (**indexata in PubMed/Medline**)
6. **Antoniou SA, Azoicai D**. Evaluation of therapeutic effect in chronic obstructive pulmonary disease (COPD) by assessment of quality of life: methodological considerations]. *Rev Med Chir Soc Med Nat Iasi*. 2010 114(1): 20-8 (**Indexata in PubMed/Medline**)
7. **Antoniou SA** Reducing mortality for chronic obstructive pulmonary disease: role of statins and angiotensin-converting enzyme inhibitors. *Expert Rev Pharmacoecon Outcomes Res* 2009 9(6): 523-5 (**Indexata in PubMed/Medline**)
8. **Antoniou SA** Antibiotics and reduced risk of COPD re-exacerbations. *Expert Rev Pharmacoecon Outcomes Res* 2009 9(4): 309-11(**Indexata in PubMed/Medline**)
9. **Antoniou SA**. Long-term bronchodilator inhaled therapy in COPD: the role of tiotropium bromidum. *Rev Recent Clin Trials*. 2009 4(2):89-98(**Indexata in PubMed/Medline**)
10. **Antoniou SA, Bararu T, Zizilaş G, Mihăescu T**. [Inhaled therapy via nebulization: practical issues]. *Pneumologia*. 2007 56(3):143-6. (**Indexata in PubMed/Medline**)
11. **Antoniou SA**. Imatinib mesilate for the treatment of hypereosinophilic syndromes. *Current Opinion in Investigational Drugs* 2006 7(11): 980-984, ISSN: 1354-3784 (**Indexata in PubMed/Medline**)
12. **Antoniou SA**. Self-management programs in chronic obstructive pulmonary disease: do they have a sustained effect on health resource utilization? *Expert Rev Pharmacoecon Outcomes Res* 2006 6(2):155-7(**Indexata in PubMed/Medline**)

13. **Antoniou SA.** Roflumilast for the treatment of chronic obstructive pulmonary disease. Therapy. 2006. 3(2): 247-250 (**Indexata Excerpta Medica, Scopus**).
14. **Antoniou SA.** Roflumilast for the treatment of chronic obstructive pulmonary disease. Current Opinion in Investigational Drugs 2006 7 (5): 412-7(**Indexata PubMed/Medline**)
15. **Antoniou SA.** Outcomes of adult domiciliary oxygen therapy in pulmonary diseases. Expert Rev Pharmacoecon Outcomes Res 2006 6(1):59-66(**Indexata in PubMed/Medline**)
16. **Antoniou SA.** Eligibility testing for long-term domiciliary oxygen therapy: more often, more effective? Expert Rev Pharmacoecon Outcomes Res 2006 6(1):33-5(**Indexata in PubMed/Medline**)
17. **Antoniou, SA.** Bosentan for treatment of pulmonary arterial hypertension (I). Therapy. 2005 2(6): 843-7, (**Indexata Excerpta Medica, Scopus etc**).
18. **Antoniou, SA.** Bosentan for treatment of pulmonary arterial hypertension (I). Therapy. 2005 2(6): 849-52 (**Indexata Excerpta Medica, Scopus etc**).
19. **Antoniou SA.** Self-management programs in chronic obstructive pulmonary disease: are they worthy? Expert Rev Pharmacoecon Outcomes Res. 2003 3(6):681-3(**Indexata in PubMed/Medline**)
20. **Antoniou SA.** Intravenous montelukast in asthma exacerbations: could it help? Expert Rev Pharmacoecon Outcomes Res. 2003 3(5):521-3. (**Indexata in PubMed/Medline**)
21. **Antoniou SA.** Compliance with inhalatory therapy: an increasingly recognized clinical outcome. Expert Rev Pharmacoecon Outcomes Res. 2003 3(4):449-56(**Indexata in PubMed/Medline**)
22. **Antoniou SA, Mititiuc I.** Quality of life following lung cancer surgery: what about before? Expert Rev Pharmacoecon Outcomes Res. 2003 3(4):375-7(**Indexata in PubMed/Medline**)
23. **Antoniou SA.** The START study: when to start to treat with inhaled steroids in asthma? Expert Rev Pharmacoecon Outcomes Res 2003 3(3):223-5(**Indexata in PubMed/Medline**)
24. **Antoniou SA, Mititiuc I.** Salmeterol/fluticasone combination in COPD: is together better? Expert Rev Pharmacoecon Outcomes Res. 2003 3(2):121-4 (**Indexata in PubMed/Medline**)
25. **Antoniou SA.** Economic analysis of a self-management asthma plan: is it really effective if further assessed? Expert Rev Pharmacoecon Outcomes Res 2003 3(2):117-9 (**Indexata in PubMed/Medline**)
26. **Antoniou SA, Mihaescu T, Carone M, Donner CF.** Health status in COPD: current data and future trends. Expert Rev Pharmacoecon Outcomes Res. 2003 3(1):57-65 (**Indexata in PubMed/Medline**)
27. **Antoniou SA, Mihaescu T** Hospitalizations and mortality in the Lung Health Study. Expert Rev Pharmacoecon Outcomes Res. 2002 2(6):523-6 (**Indexata in PubMed/Medline**)
28. **Antoniou SA, Donner CF.** Fluticasone propionate in COPD airway inflammation: there is a partial effect. Expert Rev Pharmacoecon Outcomes Res. 2002 2(5):415-7 (**Indexata in PubMed/Medline**)

BDI coauthor

16. Mititiuc I, Covic A, **Antoniou S**, Chifu C, Andrusca D. The link between glomerulonephritis and hydatid disease. Rev Med Chir Soc Med Nat Iasi 2002 107(2): 290-3

25.01.2021

Conf.dr Sabina Antoniu